welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy
study id #: NCT01823783
condition: Duchenne Muscular Distrophy (DMD)
Duchenne muscular dystrophy (DMD) is the most common and devastating form of muscular dystrophy, caused by an X-chromosome gene mutation resulting in the absence of the protein dystrophin. Gene therapy by exon skipping or stop codon read-through and cell therapy are at the stage of clinical assays with very promising results. Nevertheless, they will not allow a complete cure of DMD patients and they will concern only specific types of mutations. It is therefore crucial to develop other therapeutic strategies related to the natural history of the disease and targeted not on the dystrophin itself, but on the consequences of its absence. Another crucial pathophysiological pathway in DMD is muscle cell calcium homeostasis, particularly via the ryanodine recepteur (RyR1). Our study focus on the relationship between endomysial fibrosis, abnormal inflammation response and calcium homeostasis dysfunction which are not entirely established in DMD. The identification of the biological mechanisms that play a role in the severity of the phenotype, particularly endomysial fibrosis, should allow the development of targeted pharmacotherapy as a complementary strategy for the future treatment of DMD.
intervention: Muscle biopsy
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: November 7, 2012
estimated completion: June 2018
phase of development: N/A
size / enrollment: 50
- Quantification of endomysial fibrosis [Time Frame: 1 day (biopsy day)]
- quantification of the muscle inflammation [Time Frame: 1 day (biopsy day)]
• Measure of the protein (Immunofluorescence and western blot) and mRNA (qRT-PCR) expression of the following markers of muscular inflammation response
• Presence and quantification of cellular partners of inflammation and muscle regeneration (M1 (CD68/KP1) and M2 (CD206) macrophages, quiescent and activated satellite cells (CD56/NCAM) and endothelial cells (CD31/PECAM-1)).
• Boy between 2 to 15 years old.
• Lack of any infectious disease in the last week before the study.
• Consent form signed by parents. Inclusion Criteria for DMD infant
• Clinical suspicion of Duchenne Muscular Dystrophy
Inclusion Criteria for Control healthy Infant
• Lack of any antecedent of congenital cardiac, pulmonary or muscular disease including DMD.
• Subjects who are unable or unwilling to tolerate study constraints
• Parents of the subject unable or unwilling to undergo informed consent
• Subject with no rights from the national health insurance programme
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
L-citrulline and Metformin in Duchenne’s Muscular DystrophyThe purpose of the study is to show that...
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-studyCarriers of Duchenne muscular dystrophy ...
Biomarker for Duchenne Disease (BIODUCHENNE)Development of a new mass spectrometry-b...
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
(-)- Epicatechin Becker Muscular DystrophyThis is a 48-week open-label extension o...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...